Noemi Horvath

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld et al. · Journal of Clinical Oncology · 2007 · 644 citations · Full text

Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure

Andrew Spencer, H. Miles Prince, Andrew W. Roberts et al. · Journal of Clinical Oncology · 2009 · 333 citations · Full text

Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Andrew Spencer, Suzanne Lentzsch, Katja Weisel et al. · Haematologica · 2018 · 254 citations · Full text

Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo.

Amanda Farrugia, Gerald J. Atkins, Luen Bik To et al. · PubMed · 2003 · 219 citations

Immunology, Cell Death, Pathology +20

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

Silvia Ling, Edwin Lau, Ammira Al-Shabeeb et al. · Haematologica · 2011 · 127 citations · Full text